Tumor Biology

, Volume 35, Issue 4, pp 3017–3024 | Cite as

Effect of cyclin G2 on proliferative ability of prostate cancer PC-3 cell

  • D. W. Cui
  • Y. J. Cheng
  • S. W. Jing
  • G. G. Sun
Research Article


This study aimed to analyze the expression, clinical significance of cyclin G2 (CCNG2) in prostate carcinoma, and the biological effect in its cell line by CCNG2 overexpression. Immunohistochemistry and Western blot were used to analyze CCNG2 protein expression in 85 cases of prostate cancer and normal tissues to study the relationship between CCNG2 expression and clinical factors. CCNG2 lentiviral vector and empty vector were, respectively, transfected into prostate cancer PC-3 cell line. Reverse transcription–polymerase chain reaction (RT-PCR) and Western blot were used to detect the mRNA level and protein of CCNG2. MTT assay and cell cycle were also conducted as to the influence of the upregulated expression of CCNG2 that might be found on PC-3 cells biological effect. The level of CCNG2 protein expression was found to be significantly lower in prostate cancer tissue than normal tissues (P < 0.05). The level of CCNG2 protein expression was not correlated with age, PSA contention, and tumor size (P < 0.05), but it was correlated with lymph node metastasis, clinic stage, and Gleason score (P < 0.05). The result of biological function shown that PC-3 cell transfected CCNG2 had a lower survival fraction, more percentage of the G0/G1 phases, and lower CDK2 protein expression compared with PC-3 cell untransfected CCNG2 (P < 0.05). CCNG2 expression decreased in prostate cancer and correlated significantly with lymph node metastasis, clinic stage, and Gleason score, suggesting that CCNG2 may play important roles as a negative regulator to prostate cancer cell.


CCNG2 Prostate cancer Prognosis Tumor metastasis 



This research was supported by the Specialized Research Fund for the Doctoral Program of Higher Education of China. The study members, their families, and their friends are thanked for their continuing support.

Conflicts of interest



  1. 1.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. 2000. CA Cancer J Clin. 2000;50:7–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The national cancer data base report on prostate carcinoma after the peak in incidence rates in the US. Cancer. 1998;83:1679–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Ahmed S, Al-Saigh S, Matthews J. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. Mol Cancer Res. 2012;10:636–48.PubMedCrossRefGoogle Scholar
  4. 4.
    Bates S, Rowan S, Vousden KH. Characterization of human cyclin G1 and G2: DNA damage inducible genes. Oneogene. 1996;13:1103–9.Google Scholar
  5. 5.
    Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF. Cyclin G1 and cyclinG2 comprise a new family of cyclins with contrasting cycle-regulated expression. J Biol Chem. 1996;271:6050–61.PubMedCrossRefGoogle Scholar
  6. 6.
    Kim Y, Shintani S, Kohno Y, Zhang R, Wong DT. Cyclin G2 dysregulation in human oral cancer. Cancer Res. 2004;64:8980–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Cui XF, Liu AJ, Xu ZM. Expression of Cyclin G2 and its clinical significance in laryngeal squamous cell carcinoma. J Clin Torhinolaryngology. 2009;23:277–9.Google Scholar
  8. 8.
    Shan G, Shan SG, Zhang XB. Expression and clinical significance of cyclin G1 and cyelinG2 in transitional cell carcinoma of bladder. Chin J Histochem Cytochem. 2009;18:268–72.Google Scholar
  9. 9.
    Choi MG, Noh JH, An JY, Hong SK, Park SB, Baik YH, et al. Expression levels of cyclinG2, but not cyclin E, correlate with gastric progression. J Surg Res. 2009;157:168–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Shi W, Yu KR, Wu GY, Zhang H. Expression of CCNG2 in gastric carcinoma and its relationship with prognosis. Chin J Cell Biol. 2011;33:994–7.Google Scholar
  11. 11.
    Song YL, Hu GH. CyclinG2: correlation with head and neck neoplasms. Int J Otolaryngology-Head Neck Surg. 2006;30:8–11.Google Scholar
  12. 12.
    Le XF, Arachehige-Don AS, Mao W, Horne MC, Bast Jr RC. Roles of human epidermal growth factor receptor 2, c-Jun NH2- terminal kinase, PhosPhoinositide 3-kinase, and P7056 kinase pathways in regulation of cyclinG2 expression in human breast cancer cells. Mol Cancer Ther. 2007;6:2843–57.PubMedCrossRefGoogle Scholar
  13. 13.
    Martinez GACL, Marqués M, García Z, Campanero MR, Carrera AC. Control of cyclinG2 mRNA expression by forkhead transcription factors: novel mechanism for cell cycle control by phosphoinositide 3-kinase and forkhead. Mol Cell Biol. 2004;4:2181–9.CrossRefGoogle Scholar
  14. 14.
    Chen J, Yusuf L, Andersen HM, Fruman DA. FOXO transcription factors cooperate withδEF1 to activate growth suppressive genes in B-lymphocytes. J Immunol. 2006;76:2711–21.Google Scholar
  15. 15.
    Xu G, Bernaudo S, Fu G, Lee DY, Yang BB, Peng C. CyclinG2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kilase 7. Mol Biol Cell. 2008;9:4968–79.CrossRefGoogle Scholar
  16. 16.
    Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, et al. Mechanistic insight intoWEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol. 2009;7:1176–85.CrossRefGoogle Scholar
  17. 17.
    van Duijn PW, Ziel-van der Made AC, van der Korput JA, Trapman J. PTEN- mediated Gl cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators. Prostate. 2010;70:135–46.PubMedGoogle Scholar
  18. 18.
    Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, et al. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor mediated cell cycle arrest. J Biol Chem. 1997;272:12650–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, Ortiz L, et al. Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B′ subunits in active complexes and induces nuclear aberrations and a Gl/S phase cell cycle arrest. J Biol Chem. 2002;2779:27449–67.CrossRefGoogle Scholar
  20. 20.
    DonAS A, Dallapiazza RF, Bennin DA, Brake T, Cowan CE, Horne MC. CyclinG2 is a centrosome-associated nucleocytoplasmic shuttling protein that influences microtubule stability and induces a P53-dependent cell cycle arrest. Exp Cell Res. 2006;312:4181–204.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • D. W. Cui
    • 1
  • Y. J. Cheng
    • 2
  • S. W. Jing
    • 2
  • G. G. Sun
    • 3
  1. 1.Department of Urinary SurgeryTangshan Works HospitalTangshanChina
  2. 2.Department of RadiotherapyThe Fourth Hospital of Hebei Medical UniversityShijiazhuangChina
  3. 3.Department of ChemoradiotherapyTangshan People’s HospitalTangshanChina

Personalised recommendations